摘要
目的:探究经导管肝动脉化疗栓塞介入治疗联合阿帕替尼对原发性肝癌患者的影响。方法:选取2019年6月-2020年6月在武汉亚心总医院肿瘤科住院治疗的原发性肝癌患者共80例,随机分为观察组与对照组,各40例。观察组采用经导管肝动脉化疗栓塞介入治疗联合阿帕替尼治疗,对照组采用经导管肝动脉化疗栓塞介入治疗。对比两组患者的疾病控制情况、生活质量、血管内皮生长因子、血清CXC趋化因子配体9(serum levels of CXC chemokine ligand 9,CXCL9)水平。结果:比较两组患者治疗后3、6、9个月疾病的控制率,观察组显著高于对照组(P<0.05);治疗后观察组患者生活质量各维度评分显著高于对照组(P<0.05);治疗前,两组患者血管内皮生长因子变化比较,差异无统计学意义(P>0.05);治疗1个月后,观察组血管内皮生长因子明显低于对照组(P<0.05);治疗前,两组患者血清CXCL9水平比较,差异无统计学意义(P>0.05);治疗1个月后,观察组血清CXCL9水平明显低于对照组,差异有统计学意义(P<0.05)。结论:经导管肝动脉化疗栓塞介入治疗联合阿帕替尼能够提升原发性肝癌患者的疾病控制率及生活质量,同时降低血管内皮生长因子及血清CXCL9水平。
Objective:To explore the effect of interventional therapy with transcatheter hepatic arterial chemoembolization combined with Apatinib in patients with primary liver cancer.Method:A total of 80 patients with primary liver cancer hospitalized in the oncology department of Wuhan Yaxin General Hospital from June 2019 to June 2020 were randomly divided into observation group and control group,40 cases in each group.The observation group was treated with interventional therapy with transcatheter hepatic artery chemoembolization combined with Apatinib,and the control group was treated with interventional therapy with transcatheter hepatic artery chemoembolization.The disease control situation,quality of life,vascular endothelial growth factor and serum levels of CXC chemokine ligand 9(CXCL9)levels of the two groups were compared.Result:After 3,6 and 9 months of treatment,the disease control rates in the observation group were significantly higher than those in the control group(P<0.05).After treatment,the scores of all dimensions of quality of life in the observation group were significantly higher than those in the control group(P<0.05).Before treatment,there was no significant difference in the changes of vascular skin growth factor between the two groups(P>0.05).After one month of treatment,vascular endothelial growth factor in the observation group was significantly lower than that in the control group(P<0.05).Before treatment,there was no significant difference in serum CXCL9 levels between the two groups(P>0.05).After one month of treatment,the level of serum CXCL9 in the observation group was significantly lower than that in the control group(P<0.05).Conclusion:Interventional therapy with transcatheter hepatic arterial chemoembolization combined with Apatinib can improve the disease control rate and quality of life of patients with primary liver cancer,and reduce the levels of vascular endothelial growth factor and serum CXCL9.
作者
朱席政
徐辉
ZHU Xizheng;XU Hui(Wuhan Yaxin General Hospital,Wuhan 430056,China;不详)
出处
《中外医学研究》
2022年第10期48-51,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
介入治疗
经导管肝动脉化疗栓塞
阿帕替尼
原发性肝癌
血管内皮生长因子
Interventional therapy
Transcatheter hepatic arterial chemoembolization
Apatinib
Primary liver cancer
Vascular endothelial growth factor
